A cross-sectional examination of choice and behavior of veterans with access to free medicinal cannabis

References

• National Academies of Sciences, Engineering and M. The health effects of cannabis and cannabinoids. Washington, D.C.: National Academies Press; 2017.
   Google Scholar
• Hill KP. Medical marijuana for treatment of chronic pain and other medical and psychiatric problems. JAMA. 2015 Jun 23;313(24):2474. doi:10.1001/jama.2014.17152
   PubMed Web of Science ®Google Scholar
• Ellis RJ, Toperoff W, Vaida F, et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology. 2009 Feb 6;34(3):672–80. doi:10.1038/npp.2008.120
   PubMed Web of Science ®Google Scholar
• Pertwee R. The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes. 2006;30:13–18. doi:10.1038/sj.ijo.0803272
   PubMed Web of Science ®Google Scholar
• Nguyen BM, Kim D, Bricker S, Bongard F, Neville A, Putnam B, Smith J, Plurad D. Effect of marijuana use on outcomes in traumatic brain injury. Am Surg. 2014;80(10):979–83.
   Google Scholar
• Iuvone T, Esposito G, Esposito R, Santamaria R, Di Rosa M, Izzo AA. Neuroprotective effect of cannabidiol, a non-psychoactive component from cannabis sativa, on β-amyloid-induced toxicity in PC12 cells. J Neurochem. 2004 Apr 1;89(1):134–41. doi:10.1111/j.1471-4159.2003.02327.x
   PubMed Web of Science ®Google Scholar
• Fagherazzi E V., Garcia VA, Maurmann N, et al. Memory-rescuing effects of cannabidiol in an animal model of cognitive impairment relevant to neurodegenerative disorders. Psychopharmacology (Berl). 2012 Feb 26;219(4):1133–40. doi:10.1007/s00213-011-2449-3
   PubMed Web of Science ®Google Scholar
• Mechoulam R, Shohami E. Endocannabinoids and traumatic brain injury. Mol. Neurobiol. 2007;36(1):68–74
   Google Scholar
• Jutras-Aswad D, Prud’homme M, Cata R. Cannabidiol as an intervention for addictive behaviors: a systematic review of the evidence. Subst Abus Res Treat. 2015;9:33.
   Web of Science ®Google Scholar
• Bhardwaj AK, Allsop DJ, Copeland J, et al. Randomised Controlled Trial (RCT) of cannabinoid replacement therapy (Nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol. BMC Psychiatry. 2018 Dec 18;18(1):140. doi:10.1186/s12888-018-1682-2
   PubMed Web of Science ®Google Scholar
• Hurd YL, Yoon M, Manini AF, Hernandez S, Olmedo R, Ostman M, Jutras-Aswad D. Early phase in the development of cannabidiol as a treatment for addiction: opioid relapse takes initial center stage. Neurotherapeutics. 2015;12(4):807–15.
   Google Scholar
• Ren Y, Whittard J, Higuera-Matas A, Morris CV, Hurd YL. Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances. J Neurosci. 2009 Nov 25;29(47):14764–69. doi:10.1523/JNEUROSCI.4291-09.2009
   PubMed Web of Science ®Google Scholar
• Hill KP, Palastro MD, Gruber SA, et al. Nabilone pharmacotherapy for cannabis dependence: a randomized, controlled pilot study. Am J Addict. 2017 Dec;26(8):795–801. doi:10.1111/ajad.12622
   PubMed Web of Science ®Google Scholar
• Vandrey R, Stitzer ML, Mintzer MZ, Huestis MA, Murray JA, Lee D. The dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users. Drug Alcohol Depend. 2013 Feb 1;128(1–2):64–70. doi:10.1016/j.drugalcdep.2012.08.001
   PubMed Web of Science ®Google Scholar
• Katsidoni V, Anagnostou I, Panagis G. Cannabidiol inhibits the reward-facilitating effect of morphine: involvement of 5-HT1A receptors in the dorsal raphe nucleus. Addict Biol. 2013 Mar 1;18(2):286–96. doi:10.1111/j.1369-1600.2012.00483.x
   PubMed Web of Science ®Google Scholar
• Loflin MJ, Babson KA, Bonn-Miller MO. Cannabinoids as therapeutic for PTSD. Curr Opin Psychol. 2017;14:78–83.
   Web of Science ®Google Scholar
• Jetly R, Heber A, Fraser G, Boisvert D. The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: a preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology. 2015 Jan 1;51:585–88. doi:10.1016/j.psyneuen.2014.11.002
   PubMed Web of Science ®Google Scholar
• Chhatwal JP, Davis M, Maguschak KA, Ressler KJ. Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear. Neuropsychopharmacology. 2005;30(3):516.
   Google Scholar
• Campos AC, Guimarães FS. Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. Psychopharmacology (Berl). 2008;199(2):223–30. doi:10.1007/s00213-008-1168-x
   PubMed Web of Science ®Google Scholar
• Das RK, Kamboj SK, Ramadas M, et al. Cannabidiol enhances consolidation of explicit fear extinction in humans. Psychopharmacology (Berl). 2013;226(4):781–92. doi:10.1007/s00213-012-2955-y
   PubMed Web of Science ®Google Scholar
• VanElzakker MB, Kathryn Dahlgren M, Caroline Davis F, Dubois S, Shin LM. From Pavlov to PTSD: the extinction of conditioned fear in rodents, humans, and anxiety disorders. Neurobiol Learn Mem. 2014 Sep;113:3–18. doi:10.1016/j.nlm.2013.11.014
   PubMed Web of Science ®Google Scholar
• A. Rabinak C, Phan KL. Cannabinoid modulation of fear extinction brain circuits: a novel target to advance anxiety treatment. Curr Pharm Des. 2014;20(13):2212–7.
   Google Scholar
• Lucas P. Cannabis as an adjunct to or substitute for opiates in the treatment of chronic pain. J Psychoactive Drugs. 2012 Apr;44(2):125–33. doi:10.1080/02791072.2012.684624
   PubMed Web of Science ®Google Scholar
• Lucas P, Walsh Z, Crosby K, et al. Substituting cannabis for prescription drugs, alcohol and other substances among medical cannabis patients: the impact of contextual factors. Drug Alcohol Rev. 2016 May 1;35(3):326–33. doi:10.1111/dar.12323
   PubMed Web of Science ®Google Scholar
• Bachhuber MA, Saloner B, Cunningham CO, Barry CL. B C, PO C. Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999–2010. JAMA Intern Med. 2014 Oct 1;174(10):1668. doi:10.1001/jamainternmed.2014.4005
   PubMed Web of Science ®Google Scholar
• Boehnke KF, Litinas E, Clauw DJ. Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain. J Pain. 2016 Jun 1;17(6):739–44. doi:10.1016/j.jpain.2015.12.006
   PubMed Web of Science ®Google Scholar
• Gruber SA, Sagar KA, Dahlgren MK, Racine MT, Smith RT, Lukas SE. Splendor in the grass? A pilot study assessing the impact of medical marijuana on executive function. Front Pharmacol. 2016 Oct 13;7(OCT):355. doi:10.3389/fphar.2016.00323
   PubMed Web of Science ®Google Scholar
• Karila L, Roux P, Rolland B, et al. Acute and long-term effects of cannabis use: a review. Curr Pharm Des. 2014;20(25):4112–18. doi:10.2174/13816128113199990620
   PubMed Web of Science ®Google Scholar
• Bonn-Miller MO, Harris AHS, Trafton JA. Prevalence of cannabis use disorder diagnoses among veterans in 2002, 2008, and 2009. Psychol Serv. 2012;9(4):404–16. doi:10.1037/a0026143
   PubMed Web of Science ®Google Scholar
• Gentes EL, Schry AR, Hicks TA, et al. Prevalence and correlates of cannabis use in an outpatient VA posttraumatic stress disorder clinic. Psychol Addict Behav. 2016;30(3):415–21. doi:10.1037/adb0000154
   PubMed Web of Science ®Google Scholar
• ElSohly MA, Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci. 2005 Dec;78(5):539–48. doi:10.1016/j.lfs.2005.05.067
   PubMed Web of Science ®Google Scholar
• Russo E, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses. 2005;66(2):234–46. doi:10.1016/j.mehy.2005.08.026
   PubMed Web of Science ®Google Scholar
• Bonn-Miller MO, Boden MT, Vujanovic AA, Drescher KD. Prospective investigation of the impact of cannabis use disorders on posttraumatic stress disorder symptoms among veterans in residential treatment. Psychol Trauma Theory, Res Pract Policy. 2011;5(2):193–200. doi:10.1037/a0026621
   Web of Science ®Google Scholar
• Wilkinson ST, Stefanovics E, Rosenheck RA. Marijuana use is associated with worse outcomes in symptom severity and violent behavior in patients with posttraumatic stress disorder. J Clin Psychiatry. 2015;76(9):1174–80. doi:10.4088/JCP.14m09475
   PubMed Web of Science ®Google Scholar
• Viveros M, Marco E, File S. Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav. 2005;81(2):331–42. doi:10.1016/j.pbb.2005.01.029
   PubMed Web of Science ®Google Scholar
• Steenkamp MM, Blessing EM, Galatzer-Levy IR, Hollahan LC, Anderson WT. Marijuana and other cannabinoids as a treatment for posttraumatic stress disorder: a literature review. Depress Anxiety. 2017;34(3):207–16. doi:10.1002/da.2017.34.issue-3
   PubMed Web of Science ®Google Scholar
• Bergamaschi MM, Queiroz RHC, Chagas MHN, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology. 2011;36(6):1219–26. doi:10.1038/npp.2011.6
   PubMed Web of Science ®Google Scholar
• Babson KA, Sottile J, Morabito D. Cannabis, cannabinoids, and sleep: a review of the literature. Curr Psychiatry Rep. 2017 Apr 27;19(4):23. doi:10.1007/s11920-017-0775-9
   PubMed Web of Science ®Google Scholar
• Strasser F, Luftner D, Possinger K, et al. Comparison of orally administered cannabis extract and delta-9- tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannab. J Clin Oncol. 2006 Jul 20;24(21):3394–400. doi:10.1200/JCO.2005.05.1847
   PubMed Web of Science ®Google Scholar
• Paudel KS, Hammell DC, Agu RU, Valiveti S, Stinchcomb AL. Cannabidiol bioavailability after nasal and transdermal application: effect of permeation enhancers. Drug Dev Ind Pharm. 2010 Sep 5;36(9):1088–97. doi:10.3109/03639041003657295
   PubMed Web of Science ®Google Scholar
• Huestis MA, Cone EJ. Relationship of Δ9-tetrahydrocannabinol concentrations in oral fluid and plasma after controlled administration of smoked cannabis. J Anal Toxicol. 2004;28(6):394–99.
   Google Scholar
• Hollister LE, Gillespie HK, Ohlsson A, Lindgren JE, Wahlen A, Agurell S. Do plasma concentrations of delta 9-tetrahydrocannabinol reflect the degree of intoxication? J Clin Pharmacol. 1981 Aug 9;21(8–9Suppl):171S–177S. doi:10.1002/j.1552-4604.1981.tb02593.x
   PubMed Web of Science ®Google Scholar
• Chait LD, Zacny JP. Reinforcing and subjective effects of oral Δ9-THC and smoked marijuana in humans. Psychopharmacology (Berl). 1992 Jun;107(2–3):255–62. doi:10.1007/BF02245145
   PubMed Web of Science ®Google Scholar
• Hart C, Ward A, Haney M, Comer S, Foltin R, Fischman M. Comparison of smoked marijuana and oral Δ 9 -tetrahydrocannabinol in humans. Psychopharmacology (Berl). 2002 Dec 1;164(4):407–15. doi:10.1007/s00213-002-1231-y
   PubMed Web of Science ®Google Scholar
• Pierre JM, Gandal M, Son M. Cannabis-induced psychosis associated with high potency “wax dabs.”. Schizophr Res. 2016 Apr 1;172(1–3):211–12. doi:10.1016/j.schres.2016.01.056
   PubMed Web of Science ®Google Scholar
• Pierre JM. Risks of increasingly potent Cannabis: the joint effects of potency and frequency: as THC levels rise, the risk of psychosis, cognitive deficits, and structural brain changes increases. Curr Psychiatr. 2017 Feb 1;16(2):14–21.
   Google Scholar
• Freeman TP, Winstock AR. Examining the profile of high-potency cannabis and its association with severity of cannabis dependence. Psychol Med. 2015 Nov 27;45(15):3181–89. doi:10.1017/S0033291715001269
   PubMed Web of Science ®Google Scholar
• Loflin M, Earleywine M. A new method of cannabis ingestion: the dangers of dabs? Addict Behav. 2014;39(10). doi:10.1016/j.addbeh.2014.05.013
   PubMed Web of Science ®Google Scholar
• Bradford AC, Bradford WD. Medical marijuana laws reduce prescription medication use in medicare part D. Health Aff. 2016 Jul 2;35(7):1230–36. doi:10.1377/hlthaff.2015.1661
   PubMed Web of Science ®Google Scholar
• Bradford AC, Bradford WD, Abraham A, Bagwell Adams G. Association between US state medical cannabis laws and opioid prescribing in the medicare part D population. JAMA Intern Med. 2018 May 1;178(5):667. doi:10.1001/jamainternmed.2018.0266
   PubMed Web of Science ®Google Scholar
• Bradford AC, Bradford WD. Medical marijuana laws may be associated with a decline in the number of prescriptions for medicaid enrollees. Health Aff. 2017 May 5;36(5):945–51. doi:10.1377/hlthaff.2016.1135
   Web of Science ®Google Scholar
• Wen H, medicine JH-J internal, 2018 undefined. Association of medical and adult-use marijuana laws with opioid prescribing for Medicaid enrollees. JAMA Intern Med. 2018;178(5):673–9.
   Google Scholar
• Loflin M, Earleywine M, Bonn-Miller M. Medicinal versus recreational cannabis use: patterns of cannabis use, alcohol use, and cued-arousal among veterans who screen positive for PTSD. Addict Behav. 2017;68. doi:10.1016/j.addbeh.2017.01.008.
   PubMed Web of Science ®Google Scholar
• Lachenmeier DW, Rehm J. Comparative risk assessment of alcohol, tobacco, cannabis and other illicit drugs using the margin of exposure approach. Sci Rep. 2015 Jan 30;5:8126. doi:10.1038/srep08126
   PubMed Web of Science ®Google Scholar
• Sachs J, McGlade E, Yurgelun-Todd D. Safety and toxicology of cannabinoids. Neurotherapeutics. 2015;12(4):735–46.
   Google Scholar
• Bahorik AL, Leibowitz A, Sterling SA, Travis A, Weisner C, Satre DD. Patterns of marijuana use among psychiatry patients with depression and its impact on recovery. J Affect Disord. 2017 Apr 15;213:168–71. doi:10.1016/j.jad.2017.02.016
   PubMed Web of Science ®Google Scholar
• Bonn-Miller MO, Boden MT, Bucossi MM, Babson KA. Self-reported cannabis use characteristics, patterns and helpfulness among medical cannabis users. Am J Drug Alcohol Abuse. 2014 Jan 8;40(1):23–30. doi:10.3109/00952990.2013.821477
   PubMed Web of Science ®Google Scholar
• Babalonis S, Haney M, Malcolm RJ, et al. Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers. Drug Alcohol Depend. 2017;172:9–13.
   PubMed Web of Science ®Google Scholar
• Linge R, Jiménez-Sánchez L, Campa L, et al. Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: role of 5-HT1A receptors. Neuropharmacology. 2016;103:16–26.
   PubMed Web of Science ®Google Scholar
• Burstein S. Cannabidiol (CBD) and its analogs: a review of their effects on inflammation. Bioorg Med Chem. 2015 Apr;23(7):1377–85. doi:10.1016/j.bmc.2015.01.059
   PubMed Web of Science ®Google Scholar
• Osborne AL, Solowij N, Weston-Green K. A systematic review of the effect of cannabidiol on cognitive function: relevance to schizophrenia. Neurosci Biobehav Rev. 2017 Jan 1;72:310–24. doi:10.1016/j.neubiorev.2016.11.012
   PubMed Web of Science ®Google Scholar
• Van Dam NT, Earleywine M. Pulmonary function in cannabis users: support for a clinical trial of the vaporizer. Int J Drug Policy. 2010 Nov 1;21(6):511–13. doi:10.1016/j.drugpo.2010.04.001
   PubMed Web of Science ®Google Scholar
• Loflin M, Earleywine M. no smoke, no fire : what the initial literature suggests regarding vapourized cannabis and respiratory risk. Cancer J Respir Ther. 2015;51(1):14–16.
   Google Scholar
• Haug NA, Kieschnick D, Sottile JE, Babson KA, Vandrey R, Bonn-Miller MO. Training and practices of cannabis dispensary staff. Cannabis Cannabinoid Res. 2016 Nov 1;1(1):244–51. doi:10.1089/can.2016.0024
   PubMedGoogle Scholar
• Jikomes N, Zoorob M. The cannabinoid content of legal cannabis in Washington state varies systematically across testing facilities and popular consumer products. Sci Rep. 2018 Dec 14;8(1):4519. doi:10.1038/s41598-018-22755-2
   PubMed Web of Science ®Google Scholar
• Vandrey R, Raber JC, Raber ME, Douglass B, Miller C, Bonn-Miller MO. Cannabinoid dose and label accuracy in edible medical cannabis products. JAMA. 2015 Jun 23;313(24):2491. doi:10.1001/jama.2015.6613
   PubMed Web of Science ®Google Scholar
• Bonn-Miller MO, Loflin MJE, Thomas BF, Marcu JP, Hyke T, Vandrey R. Labeling accuracy of cannabidiol extracts sold online. JAMA. 2017;318(17). doi:10.1001/jama.2017.11909
   PubMed Web of Science ®Google Scholar
• Del Boca FK, Noll JA. Truth or consequences: the validity of self–report data in health services research on addictions. Addiction. 2000 Nov 1;95(11s3):347–60. doi:10.1046/j.1360-0443.95.11s3.5.x
   PubMed Web of Science ®Google Scholar